Marchés français ouverture 1 h 59 min

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
47,35+0,93 (+2,00 %)
À la clôture : 4:00PM EDT
Connectez-vous pour publier un message.

Tout commentaire contraire à la réglementation en vigueur (et notamment tout commentaire à caractère raciste, antisémite ou diffamatoire) pourra donner lieu à la suppression de votre compte Yahoo.

Le cas échéant, certains commentaires que vous postez pourront également donner lieu à des poursuites judiciaires à votre encontre.

  • A
    Anonymous
    $ACAD conversation
    $ACAD Acadia initiated with an Overweight at Morgan Stanley on strong PDP foundation 07:36 ACAD Morgan Stanley analyst Jeffrey Hung initiated coverage of Acadia with an Overweight rating and $55 price target. Hung models peak unadjusted U.S. sales of greater than $5B for Nuplazid, which was approved in 2016 for Parkinson's disease psychosis and is likely to be approved in dementia-related psychosis in 2021, potentially expanding into a market 10x the size of PDP. The analyst believes the valuation remains attractive

    Read more at:
    https://thefly.com/n.php?id=3149145
  • S
    Stocktargetadvisor
    $ACAD conversation
    $ACAD
    Maintains SVB Leerink Outperform USD 56 » USD 52
    Reiterated by Oppenheimer Holdings Hold USD 42
  • I
    I
    $ACAD conversation
    Smitty4 days ago
    $ACAD conversation
    20+ percent of the float is shorted. This thing is going to fly... They are all buyers that have to buy!

    Reply5
  • M
    Myers
    YUMMY !!

    ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results $ACAD https://seekingalpha.com/pr/17680806
    ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
    seekingalpha.com
  • l
    longvrts
    $ACAD conversation
    Report out: mechanism of MeCP2 gene regulation in autistic disorder patients (MeCP2 is the target for Trofinetide recently licensed by $ACAD for Rett syndrome):

    Behav Sci (Basel). 2018 Aug 15;8(8). pii: E75. doi: 10.3390/bs8080075.

    Alterations in the MicroRNA of the Blood of Autism Spectrum Disorder Patients: Effects on Epigenetic Regulation and Potential Biomarkers.

    Vaccaro TDS1, Sorrentino JM2, Salvador S3, Veit T4, Souza DO5, de Almeida RF6.

    Abstract
    Aims: Autism spectrum disorder (ASD) refers to a group of heterogeneous brain-based neurodevelopmental disorders with different levels of symptom severity. Given the challenges, the clinical diagnosis of ASD is based on information gained from interviews with patients' parents. The heterogeneous pathogenesis of this disorder appears to be driven by genetic and environmental interactions, which also plays a vital role in predisposing individuals to ASD with different commitment levels. In recent years, it has been proposed that epigenetic modifications directly contribute to the pathogenesis of several neurodevelopmental disorders, such as ASD. The microRNAs (miRNAs) comprises a species of short noncoding RNA that regulate gene expression post-transcriptionally and have an essential functional role in the brain, particularly in neuronal plasticity and neuronal development, and could be involved in ASD pathophysiology. The aim of this study is to evaluate the expression of blood miRNA in correlation with clinical findings in patients with ASD, and to find possible biomarkers for the disorder. Results: From a total of 26 miRNA studied, seven were significantly altered in ASD patients, when compared to the control group: miR34c-5p, miR92a-2-5p, miR-145-5p and miR199a-5p were up-regulated and miR27a-3p, miR19-b-1-5p and miR193a-5p were down-regulated in ASD patients. Discussion: The main targets of these miRNAs are involved in immunological developmental, immune response and protein synthesis at transcriptional and translational levels. The up-regulation of both miR-199a-5p and miR92a-2a and down-regulation of miR-193a and miR-27a was observed in AD patients, and may in turn affect the SIRT1, HDAC2, and PI3K/Akt-TSC:mTOR signaling pathways. Furthermore, MeCP2 is a target of miR-199a-5p, and is involved in Rett Syndrome (RTT), which possibly explains the autistic phenotype in male patients with this syndrome.

    https://www.ncbi.nlm.nih.gov/pubmed/30111726
    Behav Sci (Basel). 2018 Aug 15;8(8). pii: E75. doi: 10.3390/bs8080075.
    Behav Sci (Basel). 2018 Aug 15;8(8). pii: E75. doi: 10.3390/bs8080075.
    www.ncbi.nlm.nih.gov
  • I
    I
    $ACAD conversation
    Data drawn from studies of Nuplazid's clinical use to treat people with Parkinson's psychosis show it to be effective and safe, according to presentations being given at the upcoming 2018 American Academy of Neurology ANN Annual Meeting.
    Data drawn from studies of Nuplazid's clinical use to treat people with Parkinson's psychosis show it to be effective and safe, according to presentations being given at the upcoming 2018 American Academy of Neurology ANN Annual Meeting.
    parkinsonsnewstoday.com
  • C
    Crecy
    $ACAD conversation
    State of Alaska Department of Revenue Invests $219,000 in ACADIA Pharmaceuticals Inc. $ACAD
  • K
    Kim
    $SRPT conversation
    Highlights from RBC 2020 #biotech outlook

    Top Ideas: $GILD $GMAB $SRPT $EXEL $ACAD $OVID $MOLN $ATNX $APRE $CLIN $APTO
  • D
    Divy Dends
    $ACAD conversation
    $ACAD is being manipulated in front of earnings release so MMs can front run the stock and grab cheap shares before a 20-30% move up off these levels... taking out stops to accumulate shares on the cheap for their own book. In game theory parlance this is known as organized theft and on Wall St if you are a MM it's perfectly legal.
  • O
    OliverH
    $ACAD conversation
    Baml defends $ACAD retain our Buy rating with PO $41 (prev. $44). The key risk to our thesis is failure of ACAD to achieve our ests. We note Monday’s news raises volatility for shareholders. We will continue to speak with physicians regarding their use of Nuplazid.important we note that we have conducted several checks of Nuplazid use over the last year (see our December doctor survey in Nuplazid use). Safety has consistently been described as benign by physicians with no doctor attributing Nuplazid to patient deaths.

    (from IV board)
  • V
    Vincent
    $ACAD conversation
    YOUR CHANGES ON THE BOARD AND STOCK INFORMATION IS DISTRACTING, ANNOYING AND YOU WILL FIND THAT OTHERS FEEL THE SAME
  • @
    @RealDan
    $SNAP conversation
    toddles hhas two user names This one that has posts going back 6 months
    dd6 months ago
    $ACAD conversation
    Who are the leading pharma companies most likely to consider an acquisition and what quarter do you suspect they could occur. Price is immaterial to my question. Thank you.
    ReplyReplies (1)1
    And this 2nd one that has 5 days of posts
  • J
    James
    $ACAD conversation
    Does anyone at Yahoo listen to their customers? The message board is dying not growing with this disappointing useless change.
  • A
    Anonymous
    $ACAD conversation
    Please restore the old format
  • P
    Paladin
    $ACAD conversation
    Alzheimer's P II Trial (and Parkinson's Initial Ph III Trial)

    From my perspective:

    1) The Ph II Alzheimer's trial was very positive. The drug demonstrated significant efficacy and safety. The 12 week data also showed that neither of these elements was diminished. The lack of separation from placebo at 12 weeks was due to enhanced placebo response and not due to decreased drug response.

    2) Another major benefit from the trial was the data collected that management states is very substantial and should be of very significant value in planning a Ph III trial.

    3) The population was relatively homogeneous in that all of the patients (avg. age 86) were in one system's nursing homes and were all analyzed by the same medical team, indicating both process consistency and data reporting, leading to relative reliability of information.

    4) For those who have been around for awhile, this should ring a bell regarding the process ACAD previously went through with the first and second Parkinson Ph III trials. In 2010 ACAD reported initial results on the first Ph III Parkinson's trial, and those results showed that the drug failed it's primary end point. The reason was that although the drug preformed, after six weeks the placebo arm showed improvement as well, and thus their was no significant separation. As I recall, at the time it was felt that part of an explanation for this was perhaps due to the increased attention the patients received as a result of being in the trial, along with a need to change the criteria for initial patient selection. In any event, with an improved trial design the following redesigned Ph III trial, using the data collected from the initial Ph III trial, demonstrated significant success and led to FDA approval.

    5) It should also be noted that one of the outcomes of the successful Ph III Parkinson's trial was that the family caregivers for the Parkinson patients often felt that as a result of the improved situation with regard to the patients psychosis, that they would more likely continue with home care as compared to nursing home care. 100% of the patients in the Alzheimer's trial were already in nursing homes. It is very likely that this will not be the case in the next Ph III trial.

    5) In summary, this is a breakthrough drug that clearly demonstrated efficacy for Alzheimer's Psychosis as well a safety profile that was very consistent with previous trials. Armed with substantial reliable data, the next Ph III trial....well, time will tell, but I am encouraged by what has happened to date.

    Paladin
  • I
    I
    $ACAD conversation
    No change in FDA's position on Parkinson's drug Nuplazid $ACAD
  • A
    AIKIDO
    AQST Wooow HCW price target $35 FDA approval comes early for ALS drug could top 500% upside or even more cause the float is tiny. $KRTX $MYOV $MDCO $AMRN $ACAD $SGEN , biotech rising
  • M
    Marco
    $ACAD conversation
    Not only the new format completely sucks but it appears that a ton of messages disappeared. Why Yahoo, why? Things worked well before, you had to ruin a good thing, idiots.
  • L
    Larry
    $ACAD conversation
    Pfizer of course starts buyout talk at $44, knowing Julian Baker & Co want $60.00. As Acadia burns through cash, they will settle on $50 to $55. Soon.
  • G
    Gloria
    $ACAD conversation
    Here's what we've all been waiting for and what do ACAD investors do? What they always do—sell. ACAD was up over $9 when I signed on today, now up less than $6 and dropping every second. Why do investors always dump this stock the first chance they get? I firmly believe it's a $100 stock. Today's results only affirm that for me. GL to all the believers out there.